Glassman Wealth Services’s scPharmaceuticals SCPH Stock Holding History

Glassman Wealth Services’s Portfolio SCPH Stock Details SCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-70	Closed	–	–	1332
2019 Q1	$0	Buy	+70	New	+$240	﹤0.01%	1192

Other funds holding SCPH

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

AIM

Alambic Investment Management Belvedere, California $9.12M AUM 34.55% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Glassman Wealth Services's SCPH Position: Q2 2019 in Review

Glassman Wealth Services sold out of scPharmaceuticals (SCPH) in Q2 2019, closing a stake of 70 shares.

Glassman Wealth Services first reported a position in SCPH in Q1 2019 and held it in 1 quarter. The position peaked at $0 in Q1 2019. 31 funds tracked by Wall St. Rank hold SCPH as of Q2 2019.

Glassman Wealth Services reported no remaining scPharmaceuticals position as of Q2 2019 after selling out during the quarter.
Glassman Wealth Services sold 70 scPharmaceuticals shares in Q2 2019.
Glassman Wealth Services first reported a position in scPharmaceuticals in Q1 2019 and held it in 1 quarter.
Glassman Wealth Services's scPharmaceuticals position peaked at $0 in Q1 2019.
31 funds tracked by Wall St. Rank held scPharmaceuticals as of Q2 2019.

Based on Glassman Wealth Services's 13F filing for Q2 2019, filed 8 Aug 2019.